(AMEXSymbolXCR)Presentation–WilliamBlairSmallCap.pptVIP

* * * * Company Near-Term Milestones Hospital Mobile Hemodialysis Device Functional Prototype (completed) Q4, 2007 Pre-Production Prototype Q1, 2009 FDA 510(k) submission Q3, 2009 Commercialization target Q1, 2010 Home Portable Hemodialysis Device Functional Prototype (completed) Q4, 2007 Pre-Production Prototype Q1, 2009 Home Use Clinical trial complete Q4, 2010 Home Use FDA 510(k) submission Q1, 2011 Commercialization target Q3, 2011 * NxStage Medical (NXTM) Emerging growth hemodialysis company “System One” device Home hemo.: est. 2,500 patients; 1.0% of market Hospital CRRT for acute renal failure Financial Metrics $201M market capitalization @ 10/6/08 1.9x trailing twelve months revenues (incl. Medisystems Q4, ‘07) 1.6x annualized Q2, 2008 revenues Quarter ended June 30, 2008 financial highlights $26.4M in cash ($30 million long-term debt), $14.0 cash used $13.4M operating loss Recent Private Equity Financing of $43 million * Fresenius Acquisition of Renal Solutions $190 million purchase price $100 million at closing $60 million in one year, $30 million contingency Sorbent technology Allient device Cleared by FDA over two years ago Not brought to market Why significant for Xcorporeal Suggests sorbent technology valuable High acquisition price for “scarce” assets * Xcorporeal Highlights Extra-corporeal medical devices that could replace the function of failing or failed organs Multiple initial products Mobile Hospital Hemodialysis device Portable Home Hemodialysis device Wearable Artificial Kidney First U.S. 510(k) filing anticipated Q1, 2009 Minimal to low risk strategy Prototype device tested successfully Well defined and straightforward regulatory strategy Well delineated reimbursement codes Multi-billion dollar, clearly defined markets * * * * * * * * * * * * * Prevalence 200,000/year in the U.S. with 50% mortality; majority hospitalized in ICUs Growing at 10% per year due to aging population and increasing severity of hospitalized patient